Please upgrade your browser.
With six agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress in treating this disease. However, the goal of cure remains elusive, and the agents nearest approval (i.e., axitinib and tivozanib) abide by the same paradigm as existing drugs (i.e., inhibition of VEGF or mTOR signaling).
The aim of the present study is to compare the oncologic outcomes after TE and RN in pT1 RCCs.
To evaluate the role of PAX-2, a renal tubular cell transcription factor, in the diagnosis of metastatic RCC.
Pharmacological Inhibition of Cyclin Dependent Kinases Causes p53 Dependent Apoptosis in Renal Cell Carcinoma
We evaluated the effect of roscovitine (Sigma-AldrichÂ®), a pharmacological inhibitor of cyclin dependent kinase, on renal cell carcinoma cell lines in vitro.
The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
Inhibitors of TORC1 have been shown to be active in patients with metastatic renal cell carcinoma (RCC).
Of course, Bro says, with growth comes the risk of opportunism. KCA is working hard to assure that patients are served by organizations that subscribe to the highest ethical standards. Weve started a new web page where the public can report suspicious behavior.
Researchers applied their new single-cell sequencing (SCS) method to identify the genetic characteristics of clear cell renal cell carcinoma...
Lift for Life is the signature event of Uplifting Athletes, a nonprofit organization created by Penn State Football student-athletes. Their mission is to align college football with rare diseases and recognize them as a national priority. Mechanicsburg Senior High School students have joined the effort of the Penn State chapter to raise money and promote awareness for the prevention, diagnosis, and treatment of kidney cancer. This rare disease has directly affected several staff members at Mechanicsburg Area Senior High in recent years. Don Shirley, the inspiration behind the Lift for Life initiative, lost his decade long battle with kidney cancer on October 17, 2005. He was 55 years old. His death has strengthened our resolve to continue his work. Compared to more recognized diseases, there is very limited funding for kidney cancer. All proceeds raised by the Lift for Life event benefit the Kidney Cancer Association. Since 2003, over $400,000 has been raised for this cause, and as a result, a number of new breakthroughs have been developed in the fight against this deadly disease.
A retrospective subgroup analysis was performed to evaluate the efficacy and safety of sorafenib in patients in TARGET who received treatment for >1year.
Several studies have reported the substantial prevalence of sunitinib-induced thyroid dysfunction.
|NeonCRM by Neon One|